Second line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
|
|
- Lesley Wilcox
- 5 years ago
- Views:
Transcription
1 Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
2 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Novartis, Pfizer, Pierre Fabre N/A Astellas, BMS, EUSA Pharma, Ipsen, Janssen, MSD, Novartis, Pfizer N/A BMS, EUSA Pharma, Novartis, Pfizer Astellas, Ipsen, Janssen, MSD, Pfizer Astellas, EUSA Pharma, Ipsen, Janssen, MSD, Novartis, Pfizer, Sanofi
3 Second line hormone therapies The biology of castration-resistance Hormone therapies in clinical practice Abiraterone acetate Enzalutamide Pre and post docetaxel Next steps: Predicting response and resistance Novel agents
4 Tumor volume & activity Current treatment landscape Abi 302 Enza PREVAIL Radium ALSYMPCA Abi 301 Enza AFFIRM Cabazitaxel TROPIC Radium ALSYMPCA Docetaxel chemo
5 Phase III CRPC Trials Showing OS Benefit Drug Prior Therapy Symptom Improvement/D elay Control OS Median Δ (Months) HR Docetaxel Chemo-naïve + MTX Sipuleucel-T +/- chemo - Placebo Cabazitaxel Post-docetaxel +/- MTX Abiraterone Post-docetaxel + Prednisone Enzalutamide Post-docetaxel + Placebo Radium-223 +/- chemo + Placebo Abiraterone Chemo-naïve + Prednisone Enzalutamide Chemo-naïve + Placebo Courtesy of Arun Azad
6 Androgens and prostate cancer Prostate cancer is driven by androgen receptor signaling Testosterone stimulation Normal prostate cell Prostate cancer cell This provides targets for blocking testosterone production and / or receptor
7 Testosterone suppression Testosterone Level Patients on LHRH analogues will achieve castrate levels of circulating testosterone (< 50ng/dl, < 2.0nM)
8 Aim of second line hormone treatment Prostate cancer cell Dihydrotestosterone Heat-shock protein Cytoplasm Nucleus Coactivator Androgen-response element AR Prostate cancer cell in CRPC Androgen deprivation Amplified AR Mutated AR therapy alone is insufficient Coactivator Cytokines to prevent growth of prostate cancer Other ligands PTEN Prostate cancer is deemed Pathways involving AR Hormone refractory Castration resistant Neuropeptides Bad Growth factors Bcl-2 So what is happening biologically that additional Pathways bypassing AR hormone therapies need to overcome? PI3K Akt Overexpression of Bcl-2 Neuroendocrine-like cells
9 Biology of castration resistant prostate cancer CRPC Prostate cancer cell Prostate cancer cell in CRPC Dihydrotestosterone Heat-shock protein Cytoplasm Nucleus AR Amplified AR Pathways involving AR Mutated AR Coactivator Cytokines Growth factors Other ligands PTEN Bad PI3K Akt Coactivator Bcl-2 Androgen-response element Pathways bypassing AR Overexpression of Bcl-2 Neuropeptides Neuroendocrine-like cells
10 One of the other issues in CRPC: Multiple sources of androgens Historic view Endocrine Gonadal Adrenal Testosterone AR Endocrine Gonadal Current view Microenvironment Intracrine Testosterone Adrenal AR Intracrine production Steroid metabolism Danila DC et al. J Clin Oncol. 2010;28:52(suppl). Abstract 4635
11 Castration-resistant not hormone-resistant High levels of intratumoural androgens and persistent AR signalling despite castration Androgens in prostate tissue Metastatic tissue samples (3 sites of metastasis from 4 patients) were acquired from patients with castrate testosterone levels DHT, dihydrotestosterone; T, testosterone CRPC pts have a rising PSA at progression PSA is an androgen regulated gene related to AR transcription Mostaghel et al. Urol Oncol 2009; 27(3):
12 Probability of survival This is why its important to maintain castrate testosterone levels after progression (ie to continue on ADT) Retrospective analysis (N = 341) showed that stopping medical castration was predictive of shorter survival No orchidectomy, hormone therapy discontinued prior to study entry Orchidectomy plus continued hormonal therapy Mos Recommendation: Patients requiring second line hormone therapy should continue androgen suppression after progression on ADT Taylor CD, et al. J Clin Oncol. 1993;11:
13 Second line hormone therapies The biology of castration-resistance Hormone therapies in clinical practice Abiraterone acetate Enzalutamide Pre and post docetaxel Next steps: Predicting response and resistance Novel agents
14 Tumor volume & activity Current treatment landscape Abi 302 Enza PREVAIL Radium ALSYMPCA Abi 301 Enza AFFIRM Cabazitaxel TROPIC Radium ALSYMPCA Docetaxel chemo
15 Abiraterone Acetate: an androgen biosynthesis inhibitor that inhibits all three sources of androgens Testes Adrenal gland Prostate tumour cells
16 COU-AA-302: Phase III RCT pre-docetaxel of abiraterone + pred vs pred alone Randomised 1:1 Patients with mcrpc progressing on ADT No prior chemo No visceral mets (N = 1088) Abiraterone 1000 mg PO daily + pred 5mg bd (n = 546) Placebo PO daily + pred 5mg bd (n = 542) Co-primary endpoint: OS and rpfs (central review) Key secondary endpoints: time to PSA progression, time to cytotoxic chemo, time to opiate use, time to PS deterioration Ryan et al. NEJM 2013; Lancet 2015
17 COU-AA-302: Overall survival favours abiraterone + pred AA plus pred 34 7 months [95% CI ] vs Placebo plus pred 30 3 months [ ]; HR 0 81 [95% CI ]; p=0 0033) 3.3 months improved OS with abiraterone and 19% reduction in risk of death Ryan et al. NEJM 2013; Lancet 2015
18 Subjects Without Progression or Death (%) Ryan et al. NEJM 2013; Lancet 2015 COU-AA-302: rpfs also favours abiraterone Abiraterone (median, mos): 16.5 Prednisone (median, mos): 8.3 HR (95% CI): 0.53 ( ) p Value: < Abiraterone Prednisone Months From Randomization Abiraterone Prednisone IA3 data. rpfs assessed by investigator review at prespecified IA.
19 Physiologic consequences of abiraterone Attard et al, J Clin Oncol, 2008; Ryan et al, J Clin Oncol 2010; Attard et al, JCEM 2012 Low-dose glucocorticoid replacement minimises mineralocorticoid-related toxicity by suppressing ACTH drive
20 Abiraterone Acetate: Safety Profile NB: Toxicities similar for pre- and post-docetaxel patients Ryan CJ, et al. Lancet Oncol. 2015;16:
21 Enzalutamide: mechanism of action Pure AR antagonist Greater binding to AR Prevents translocation of AR to nucleus Prevents co-activator recruitment overcomes resistance to bicalutamide in vitro 1. Tran, Science 2009; 2. Higano CS, et al. ASCO GU 2011; 3. Scher HI, et al. Lancet. 2010
22 PREVAIL: phase III RCT of enzalutamide in CRPC pre-docetaxel Randomised 1:1 Patients with mpc progressing on ADT (N = 1717) Enzalutamide 160 mg PO daily (n = 872) Placebo PO daily (n = 845) Co-primary endpoint: OS and PFS Key secondary endpoints: soft tissue response, time to PSA progression, time to cytotoxic chemo, time to first SRE Beer et al. NEJM 2014
23 PREVAIL: rpfs and OS both favour enzalutamide over placebo Radiographic PFS Overall survival 81% reduction in risk of rpfs 12mth rpfs rate 65% v 14% p < % reduction in risk of death 32.4 v 30.2 mths p < Beer et al. NEJM 2014
24 PREVAIL: Enzalutamide Safety NB: Toxicities similar for pre- and post-docetaxel patients Beer et al. NEJM 2014
25 Posterior Reversible Encephalopathy Syndrome (PRES) PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension Diagnosis of PRES requires confirmation by brain imaging, preferably MRI Enzalutamide should be discontinued
26 Is there still a role for bicalutamide in patients failing 1 st line ADT? TERRAIN RCT Ph II PFS Clear PFS benefit for enzalutamide so probably not unless other seond line optionms not available
27 Summary: Hormone therapy in CRPC Abiraterone and enzalutamide are both associated with improved overall survival & radiographic PFS Both have beneficial PROs. Good HRQoL & welltolerated with some differences in toxicity. Enzalutamide used in patients with visceral metastases as well as bone and lymph node Anecdotally abiraterone has activity in these pts 1A 1B
28 Tumor volume & activity Current treatment landscape Abi 302 Enza PREVAIL Radium ALSYMPCA Abi 301 Enza AFFIRM Cabazitaxel TROPIC Radium ALSYMPCA Docetaxel chemo
29 COU-AA-301: Phase III RCT post-docetaxel of abiraterone + pred v pred alone Randomised 2:1 Progressing mcrpc Failed 1 or 2 chemo Regimens of which 1 contained docetaxel (N = 1195) Abiraterone 1000 mg PO daily + pred 5mg bd (n = 797) Placebo PO daily + pred 5mg bd (n = 398) Primary endpoint: OS Key secondary endpoints: time to PSA progression, rpfs, PSA response de Bono et al. NEJM 2011
30 COU-AA-301: Updated analysis of OS shows benefit for abiraterone Median OS Benefit: 4.6 Months Median duration of follow-up: 20.2 months Median duration of treatment: AA, 8 months vs placebo, 4 months Fizazi, Lancet Oncology 2012
31 AFFIRM: phase III RCT of enzalutamide v placebo in CRPC after docetaxel Randomized 2:1 Patients with mcrpc progressing on docetaxel (N = 1199) Enzalutamide 160 mg PO daily (n = 800) Placebo PO daily (n = 399) Primary endpoint: OS Key secondary endpoints: PSA response, radiographic PFS, time to PSA progression Scher HI, et al. NEJM 2012
32 Survival (%) AFFIRM: OS improvement with enzalutamide in CRPC Enzalutamide Placebo HR: (95% CI: ; P < ) 37% reduction in risk of death Placebo: 13.6 mos (95% CI: ) Enzalutamide: 18.3 mos (95% CI: 17.3-NYR) Duration of OS (Mos) Median OS Benefit: 4.8 months Scher HI, et al. NEJM 2012
33 AFFIRM: Progression free survival also favours enzalutamide over placebo Radiographic PFS PSA progression Improved patient-reported outcomes; toxicity and QoL Scher HI et al. N Engl J Med 2012;367: Scher H et al, NEJM 2012
34 Hormone therapy in CRPC postdocetaxel Abiraterone with prednisolone and enzalutamide both associated with improved overall survival Improved PFS Improved patient-reported outcomes Both well tolerated but differences in toxicity profiles Personal perspective: I use both but have preferences in certain patients
35 Second line hormone therapy in CRPC: Drug characteristics Abiraterone Enzalutamide Prednisone required yes no Drug interactions (CYP) yes yes Lowers seizure threshold no yes Potential liver toxicity yes less Risk for hypertension yes yes Risk for CV events, AF yes yes Choice cannot be dictated by efficacy: Therefore choice is based on differential toxicity: Abiraterone if seizure-prone, frail, high risk for falls Enzalutamide if significant CV risk factors, contraindications to steroids Initial choice important
36 mcrpc: Abiraterone following disease progression on enzalutamide and viceversa. Low response rates Abiraterone response after prior treatment with enzalutamide 1 Enzalutamide versus docetaxel in men with CRPC progressing after abiraterone 1. Loriot Y, et al. Ann Oncol 2013;24: Suzman DL, et al. Prostate. 2014; 74:
37 Second line hormone therapies The biology of castration-resistance Hormone therapies in clinical practice Abiraterone acetate Enzalutamide Pre and post docetaxel Next steps: Overcoming resistance Including use of novel agents
38 PSA (ng/ml) A few words about resistance 1. Promiscuous AR Steroid precursors upstream of P450c17 may be androgenic ie may bind and activate mutated AR Decrease ACTH driven synthesis of steroids upstream of CYP17* by adding low dose dex Abiraterone Acetate 120 Dexamethasone 100 Dexamethasone Days on Study
39 PSA (ng/ml) A few words about resistance 1. Promiscuous AR Steroid precursors upstream of P450c17 may be androgenic ie may bind and activate mutated AR Decrease ACTH driven synthesis of steroids upstream of CYP17* by adding low dose dex Abiraterone Acetate 120 Dexamethasone 100 Dexamethasone Days on Study 2. AR splice variants: Isoforms of AR (eg Arv7) that lack the ligand-binding domain & are constitutively active Implicated in resistance to abi and enza But not taxanes
40 Ligand-independent receptor activation & bypass pathways: future directions Minimal actvity with agents targeting HER2 to date-?? Need to completely ablate androgens first. PI3K/ AKT inhibitors in PTEN lost patients in early development Drugs promoting apoptosis are in development ie. an antibody to survivin (antiapoptotic protein)
41 Conclusions and future directions Androgens and AR signaling remain critically important throughout the disease Abiraterone & enzalutamide target the AR axis Both have demonstrated improved patient-reported outcomes for patients at various stages of CRPC Both have led to a survival advantage for patients at various stages of CRPC (pre & post docetaxel) Future work involves: Enhancing our understanding of the mechanisms of resistance to these drugs Targeting other signalling pathways involved in CRPC Investigating optimal combinations & schedules with chemotherapy & other novel agents
42 Thank you
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationEvolution or revolution in the treatment of prostate cancer
Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationHave we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?
Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to
More informationAndrogens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationAnti-Androgen Therapies for Prostate Cancer: A Focused Review
Anti-Androgen Therapies for Prostate Cancer: A Focused Review Nischala Ammannagari, MD, and Saby George, MD, FACP Abstract Among men in the United States, prostate cancer is the most common malignancy
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationMapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD
Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD The University of Athens Medical School Dept of Clinical Therapeutics Prostate Cancer Evolution Chemotherapy
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationSOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc
SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationmcrpc in 2016 How to decide the optimal treatment? N. Mottet
mcrpc in 2016 How to decide the optimal treatment? N. Mottet Disclosures Conflict of interest Chairman EAU PCa guidelines..... Therefore I'm 100% biased Castrate-resistant prostate cancer (CRPC) Definition
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationUPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
More informationESMO SUMMIT AFRICA Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit
ESMO SUMMIT AFRICA 2018 Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche Merck Lilly 14 years of
More informationNAVIGATING THE mcrpc LANDSCAPE: EXPLORING KEY CLINICAL DECISION POINTS
NAVIGATING THE mcrpc LANDSCAPE: EXPLORING KEY CLINICAL DECISION POINTS Summary of presentations from the Bayer-supported satellite symposium, held at the European Association of Urology (EAU) Congress,
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationNavigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA Disclosures In compliance with accreditation, we require the following disclosures to the
More informationHave we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?
Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More information*For reprints and all correspondence: Nobuaki Matsubara, Kashiwanoha, Kashiwa, Chiba , Japan.
Japanese Journal of Clinical Oncology, 2015, 45(8) 774 779 doi: 10.1093/jjco/hyv070 Advance Access Publication Date: 15 May 2015 Original Article Original Article A multicenter retrospective analysis of
More informationNon metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,
More informationCancer de la prostate: best of 2016
Cancer de la prostate: best of 2016 Dr Christophe Massard GR2016, 3 DEC 2016 Disclosure Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech,
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationoriginal research Abstract Introduction
original research A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate Daniel Joseph Khalaf,
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationProstate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy).
Thanks to: The Medical Educator Consortium Luis Raez, MD, Florida International University 15th ed. Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Mayer Fishman,
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationCastrate resistant prostate cancer: the future of anti-androgens.
Castrate resistant prostate cancer: the future of anti-androgens. Dmitri Pchejetski 1,2*, Heba Alshaker 3, Justin Stebbing 3,4* 1. Department of Medicine, Imperial College, London, UK 2. School of Medicine,
More information- La Terapia Farmacologica -
XXV Congresso Nazionale AIRO Simposio AIRO-AIMN: Trattamento delle Metastasi Ossee nel Paziente con Tumore della Prostata "Ormonorefrattario": - La Terapia Farmacologica - Sergio Bracarda, Medical Oncology
More informationPOSITIVE CHMP OPINION FOR XTANDI (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER 1
POSITIVE CHMP OPINION FOR XTANDI (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER 1 Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationPresent and Future Perspectives in Treatment of mcrpc Patients
Present and Future Perspectives in Treatment of mcrpc Patients Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com Disclosures Astellas, Takeda, Janssen, Bouchara Recordati,
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationReview of the Stampede Results. Charles Ryan MD University of California San Francisco
Review of the Stampede Results Charles Ryan MD University of California San Francisco Se#ng and hypothesis Se
More informationOptimizing Survival in Advanced Prostate Cancer. Welcome!
Optimizing Survival in Advanced Prostate Cancer Welcome! Optimizing Survival in Advanced Prostate Cancer Cora N. Sternberg Rome, Italy Programme Understanding the heterogeneity of prostate cancer Jack
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationPaul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia
Paul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia 5-year prostate cancer specific survival rates have improved from 67% to 99% between 1974 and 2000 Excellent survival
More informationProgress in Metastatic Prostate Cancer
Integrating Current & Novel Treatment Strategies for the Management of CRPC Charles J Ryan, MD Thomas Perkins Distinguished Professor of Medicine and Urology Helen Diller Family Comprehensive Cancer Center
More informationFocus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
More information